Bone marrow aspirate concentrate — posterior iliac crest harvest, low-volume multi-site aspiration, centrifugation concentration, and CFU-F–verified MSC content for cartilage/bone applications
Bone marrow aspirate concentrate begins with a deceptively simple decision: where to stick the needle. The posterior superior iliac spine (PSIS) has emerged as the preferred harvest site over the anterior iliac crest, tibia, calcaneus, or vertebral body donor sites because comparative aspirate studies consistently show it yields higher nucleated cell counts and CFU-F density — a reflection of the PSIS containing a greater proportion of red (hematopoietically active), cancellous marrow relative to yellow (fatty) marrow found at some other accessible skeletal sites.
Marrow composition and site-dependent cellularity:
Bone marrow exists in two histologic forms: red marrow (hematopoietically active, rich in stem and stromal cells) and yellow marrow (fatty, largely hematopoietically quiescent in adults). The proportion of red-to-yellow marrow varies substantially by skeletal site and by patient age, with red marrow becoming progressively confined to the axial skeleton (vertebrae, sternum, ribs, and pelvis) and proximal long bone metaphyses as a person ages — a phenomenon relevant to why aspirate cellularity can decline meaningfully in older patients, the population most likely to need orthobiologic treatment for degenerative joint disease.
Comparative aspirate yield by site (aggregated from multiple clinical aspirate-quality studies): • Posterior iliac crest (PSIS): highest reported nucleated cell counts and CFU-F density among accessible harvest sites; the thick cancellous bone mass at the PSIS provides a larger, more consistently cellular trabecular reservoir • Anterior iliac crest: technically easier to access (patient supine), but comparative studies generally report lower cellularity than the posterior crest, felt to relate to a higher proportion of cortical-to-cancellous bone and greater historical use/instrumentation at this site in prior procedures • Proximal tibia: increasingly used for point-of-care intraoperative harvest during knee procedures due to convenient positioning, but yields substantially lower CFU-F density than the iliac crest in most comparative series • Vertebral body / calcaneus: occasionally used in research settings; not standard for routine orthobiologic BMAC harvest
Patient positioning technique: • Prone position: most common; both PSIS sites accessible without repositioning, allows straightforward bilateral harvest to increase total aspirate volume without exceeding per-site aspiration limits • Lateral decubitus: alternative when prone positioning is contraindicated or impractical (e.g., combined with a same-session procedure requiring a different position)
Landmarking and anesthesia: • The PSIS is palpated as a firm bony prominence approximately at the level of the S2 vertebra, roughly 4–5 cm lateral to the midline in most adults; a skin mark is placed after sterile prep • Local anesthetic (typically 1% lidocaine) is infiltrated not only in the skin and subcutaneous tissue but critically along the periosteum of the planned trocar path, since periosteal pain is the dominant discomfort of the procedure — inadequate periosteal anesthesia is a common cause of patient-reported pain during aspiration • Fluoroscopic guidance is used in some practices to confirm trocar trajectory and depth, particularly in patients with altered pelvic anatomy, though many experienced proceduralists perform PSIS aspiration using palpable landmarks alone
Advancing a rigid aspiration trocar through cortical bone into the cancellous marrow space is a distinct technical skill from soft-tissue needle procedures. The trocar must penetrate a genuinely hard cortical shell — felt by the operator as a sudden "give" or "pop" — after which the stylet is withdrawn and the hollow needle shaft provides direct access to the marrow sinusoids for aspiration.
Trocar/needle design:
Bone marrow aspiration needles (classically the Jamshidi needle, with numerous modern proprietary variants marketed specifically for orthobiologic harvest) consist of an outer cannula with a beveled, often threaded or trocar-tipped leading edge, and an inner stylet that occludes the lumen during insertion to prevent the cannula from becoming plugged with cortical bone debris (a "core") as it is advanced through the hard cortical shell.
Insertion sequence: 1. Skin incision (small stab incision, often <5mm) or direct trocar puncture through anesthetized skin 2. The trocar-and-stylet assembly is advanced with firm, controlled pressure combined with a gentle twisting/rotating motion through subcutaneous tissue to the periosteal surface 3. Continued firm rotational pressure advances the trocar through the cortex; the operator feels increasing resistance followed by a sudden decrease in resistance (the "pop") as the tip breaches into the softer cancellous, marrow-filled trabecular space 4. The stylet is withdrawn, leaving the hollow cannula in place with its tip positioned within the marrow cavity 5. A syringe (commonly pre-loaded with a small volume of heparin or citrate anticoagulant to prevent immediate clotting within the cannula) is attached to the cannula hub for aspiration
Common technical pitfalls: • Insufficient anesthesia depth: periosteal pain during cortical penetration is often the most painful part of the procedure for the patient if periosteal infiltration was inadequate • Excessive single-site aspiration: pulling more than 2–4 mL from a single cortical perforation site dramatically increases peripheral blood dilution of the aspirate (discussed in Stage 3) — a frequent technical error, particularly among less experienced operators trying to minimize the number of needle passes • Angle drift: because the trocar tip cannot be visualized directly (unlike ultrasound-guided soft-tissue procedures), maintaining trajectory awareness by feel and, when used, fluoroscopic confirmation is important to avoid inadvertent breach through the far cortex or into the sacroiliac joint • Clot formation in the cannula: aspiration should proceed briskly once the syringe is attached, since marrow readily clots within the needle lumen if aspiration is delayed, potentially requiring re-insertion
The single most important technical insight in modern BMAC harvest, established by biomechanical and clinical aspirate studies over the past two decades, is counterintuitive: pulling large volumes from one puncture site does not yield proportionally more stem cells — it yields progressively more diluted, lower-quality aspirate. The low-volume multi-site aspiration technique directly exploits marrow fluid dynamics to maximize the concentration of mesenchymal stromal cells delivered to the final product.
The dilution phenomenon:
When a syringe applies negative pressure at a single point within the marrow cavity, the initial aspirate draws primarily from the immediately surrounding marrow sinusoids — the richest, most concentrated source of marrow stromal and hematopoietic elements near the needle tip. As aspiration continues beyond the first few milliliters, the local marrow reservoir at that specific point is depleted, and the negative pressure increasingly draws peripheral blood inward from the surrounding vascular sinusoidal network to replace the aspirated volume. This peripheral blood is essentially devoid of marrow-derived mesenchymal stromal cells (MSCs are marrow-resident, not normally found in meaningful numbers in peripheral circulation), so continued aspiration from the same site progressively dilutes the CFU-F concentration of the sample even as total aspirate volume increases.
Key supporting evidence: • Muschler et al. (J Bone Joint Surg Am, 1997) provided foundational data demonstrating that connective tissue progenitor (CFU-F) concentration falls substantially with each successive milliliter aspirated from a single site, establishing the biological rationale for a low-volume-per-site strategy. • Hernigou et al. (subsequent studies through the 2010s, J Bone Joint Surg and related orthopedic journals) further quantified this relationship in the context of clinical BMAC harvest for orthopedic applications, reinforcing that 2 mL aliquots per aspiration site, redirected to multiple trabecular pockets, yields substantially higher total progenitor cell numbers than an equivalent total volume drawn from one or two sites.
Practical multi-site technique: • After the initial 2 mL aspiration at the first trocar position, the needle is withdrawn a few millimeters (without fully exiting the cortex) and redirected at a slightly different angle into an adjacent, undepleted trabecular pocket • This redirect-and-aspirate cycle is repeated 4–8 times per cortical entry site, and often performed bilaterally (both PSIS sites) to reach the total volume needed for a clinically effective concentrate dose • Each 2 mL aliquot is typically aspirated into a separate syringe or a shared syringe with anticoagulant, keeping total single-site volume within the range shown to preserve high progenitor cell density
Why this matters clinically: A legacy, high-volume single-site technique (pulling 20–60 mL from one puncture) was common in earlier decades and remains described in some older literature, but produces an aspirate substantially diluted with peripheral blood — delivering more total volume but not more total stem cells, and in some cases a lower absolute progenitor cell yield than a properly executed low-volume multi-site harvest of similar or even smaller total volume. This is one of the clearest examples in orthobiologics where technique, independent of the biologic product itself, materially changes the therapeutic dose delivered.
Because each individual aspiration site is deliberately limited to a small volume to preserve cell concentration, achieving a clinically useful total starting volume for concentration requires pooling aliquots from many sites — commonly both posterior iliac crests — into a shared, anticoagulated collection vessel before centrifugation.
Collection systems: • Manual syringe pooling: individual 2 mL aliquots are transferred sequentially into a larger anticoagulated collection syringe or sterile transfer bag, a technique requiring careful sterile transfer technique to avoid contamination across multiple transfers • Integrated dual-syringe or closed collection systems: several commercial BMAC kits (e.g., Arthrex Angel, EmCyte, Harvest/Terumo BCT systems adapted for marrow) use a closed aspiration circuit that draws directly into a pre-anticoagulated collection reservoir, reducing manual handling steps and contamination risk while still allowing the operator to redirect the trocar between draws
Balancing total volume against processing practicality: • Point-of-care centrifugation systems used for same-day, same-procedure BMAC (e.g., concurrent with a cartilage repair or spinal fusion procedure) are typically validated for a defined input volume range (commonly 60 mL total marrow aspirate), meaning the number of aspiration sites and per-site volume must be planned to reach that target without excessive procedure time • Larger total pooled volumes (up to 120 mL or more, sometimes with bilateral harvest) may be used when a larger final BMAC volume is needed for the target application — for example, injecting a larger joint or treating a sizable avascular necrosis lesion — but this proportionally increases procedure time and total number of needle redirections
Why anticoagulation choice still matters at this stage: • Heparin is commonly used in bone marrow collection (in contrast to PRP protocols, which avoid it) because marrow aspirate has a strong intrinsic tendency to clot rapidly upon collection due to tissue factor exposure from disrupted marrow stroma; the clinical concern about heparin's platelet-activating effects relevant to PRP is a smaller consideration here since platelet-derived growth factor content is not the primary therapeutic target of BMAC in the way it is for PRP • ACD-A/citrate is also used in many commercial kits, particularly those using automated centrifugation systems validated with citrate-based anticoagulation protocols
Quality checkpoint before centrifugation: A visual inspection for gross clot formation is performed before proceeding to centrifugation; any visible clot is generally removed (filtered) since it will not effectively separate during centrifugation and can obstruct automated processing systems.
The pooled marrow-blood mixture is centrifuged to concentrate the nucleated cell fraction — including the rare, therapeutically relevant mesenchymal stromal cells — into a small final volume suitable for injection or surgical application. Because MSCs represent only a tiny fraction of total nucleated cells in the aspirate (roughly 1 in 10,000 to 1 in 100,000 nucleated cells, far rarer than platelets in whole blood), and because no single surface marker or rapid assay can prospectively confirm true multipotent stromal cell content in real time, the colony-forming unit-fibroblast (CFU-F) assay remains the retrospective gold-standard method for verifying that a given aspirate or concentrate actually contains functional progenitor cells.
Centrifugation and concentration: • Density-gradient or differential centrifugation separates the pooled aspirate into red cell, buffy coat (mononuclear/stromal), and plasma layers, analogous in principle to PRP processing but starting from a very different cell population • Point-of-care automated systems (Arthrex Angel, EmCyte GenesisCS/BMAC, Harvest/Terumo BCT SmartPReP-based marrow systems) perform this separation in a closed, single-use disposable kit within the operating room or procedure suite, typically completing concentration in 10–15 minutes • Output: a final bone marrow aspirate concentrate volume of approximately 5–10 mL, concentrated 2–5× above the total nucleated cell (TNC) concentration of the starting aspirate, discarding the majority of red cells and excess plasma
Why flow cytometry alone is insufficient: • Surface marker panels (commonly CD90+, CD105+, CD73+, combined with CD34-/CD45-/CD14- negative selection per International Society for Cell & Gene Therapy [ISCT] minimal criteria) can identify a population phenotypically consistent with mesenchymal stromal cells, but surface marker expression alone does not confirm the functional multipotency (ability to differentiate into osteoblasts, chondrocytes, and adipocytes) that defines a true MSC • Flow cytometry also cannot distinguish live, functionally intact progenitor cells from non-viable or senescent cells expressing similar surface markers
The CFU-F assay (functional gold standard): 1. A defined volume of BMAC is plated at low density onto tissue-culture plastic in growth medium 2. Plates are incubated undisturbed for 10–14 days, allowing any plastic-adherent, clonogenic stromal progenitor cells to proliferate into discrete colonies while non-adherent hematopoietic cells are washed away with medium changes 3. Colonies are fixed, stained (commonly crystal violet), and manually counted 4. Result is expressed as CFU-F per mL of aspirate/concentrate — a direct functional readout of clonogenic progenitor cell density, though it is retrospective (results available only after the injection has already occurred) and therefore used primarily for research quality-control and manufacturing validation rather than real-time clinical decision-making 5. Reported CFU-F yields in the orthobiologic literature vary widely by patient age, harvest site, aspiration technique, and processing method — a major source of the marked product-to-product variability that complicates comparison of BMAC clinical trial outcomes across studies, similar to the PRP standardization problem
Clinical applications of BMAC: • Augmentation of cartilage repair procedures (microfracture, osteochondral autograft) — MSCs are hypothesized to support fibrocartilage and hyaline-like cartilage formation at the repair site • Treatment of early-stage avascular necrosis of the femoral head — core decompression combined with BMAC injection is one of the more established surgical applications, with some case series suggesting reduced progression to collapse in early-stage (Ficat I–II) disease • Long-bone nonunion and delayed union — percutaneous BMAC injection as an adjunct or alternative to autologous bone grafting • Intra-articular injection for knee osteoarthritis — an area of active clinical investigation, with AAOS and most orthopedic society guidelines currently characterizing evidence as limited and insufficient to support routine use outside of a shared decision-making, evidence-level discussion with patients
A critical, often underappreciated point: unlike PRP, where "platelet count" is a fast, validated, point-of-care quality metric, no rapid point-of-care assay can currently confirm true MSC content of a BMAC product at the time of injection. Clinicians and patients should understand that a given BMAC preparation's therapeutic cell content is, in practice, unverified at the time of use — it is inferred from total nucleated cell count and aspiration technique, not directly measured, which is a central limitation repeatedly flagged in evidence reviews of BMAC for orthopedic indications.